Neumora Therapeutics (NMRA) Return on Equity (2023 - 2026)

Neumora Therapeutics has reported Return on Equity for 4 years, with the latest figure at 0.03% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 2.0% year-over-year to 0.03%; the trailing twelve-month figure through Mar 2026 stood at 0.03% (down 2.0% YoY), and the FY2025 full-year result was 0.01%, down 1.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.03%, down from 0.02% in the prior quarter.
• The five-year high for Return on Equity was 3.67% in Q3 2023, with the low at 0.03% in Q1 2026.
• Average Return on Equity over 4 years is 0.3%, with a median of 0.01% recorded in 2024.
• Peak annual rise in Return on Equity reached 0 bps in 2024, while the deepest fall reached 368 bps in 2024.
• Tracing NMRA's Return on Equity over 4 years: stood at 0.0% in 2023, then plunged by 67 bps to 0.01% in 2024, then plunged by 150 bps to 0.02% in 2025, then dropped by 27 bps to 0.03% in 2026.
• The last three Return on Equity figures came in at 0.03% (Q1 2026), 0.02% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.

Peer Comparison